<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neurogene Inc — News on 6ix</title>
<link>https://6ix.com/company/neurogene-inc</link>
<description>Latest news and press releases for Neurogene Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neurogene-inc" rel="self" type="application/rss+xml" />
<item>
<title>Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-upcoming-presentation-on-the-therapeutic-rationale-for-icv-delivery-in-cns-targeted-gene-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-upcoming-presentation-on-the-therapeutic-rationale-for-icv-delivery-in-cns-targeted-gene-therapy</guid>
<pubDate>Tue, 28 Apr 2026 11:30:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families aff</description>
</item>
<item>
<title>Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-appoints-christy-shafer-as-chief-commercial-officer-and-christine-mikail-jd-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-appoints-christy-shafer-as-chief-commercial-officer-and-christine-mikail-jd-to-board-of-directors</guid>
<pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
<description>NEW YORK, April 20, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to its Board of Directors. Ms. Shafer brings more than 20 years of industry experience building and leading high-performing commercial organizations and launching therapies for ra</description>
</item>
<item>
<title>Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-reports-full-year-2025-financial-results-and-highlights-recent-updates</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-reports-full-year-2025-financial-results-and-highlights-recent-updates</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>100% of participants enrolled in Embolden™ registrational trial and >50% of participants dosed; on track to complete dosing in second quarter of 2026 NGN-401</description>
</item>
<item>
<title>Neurogene to Participate in Stifel 2026 Virtual CNS Forum</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-to-participate-in-stifel-2026-virtual-cns-forum</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-to-participate-in-stifel-2026-virtual-cns-forum</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families</description>
</item>
<item>
<title>Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-fda-breakthrough-therapy-designation-for-ngn-401-gene-therapy-for-rett-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-fda-breakthrough-therapy-designation-for-ngn-401-gene-therapy-for-rett-syndrome</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Breakthrough Therapy designation granted based on interim NGN-401 Phase 1/2 data demonstrating clinically meaningful, durable and multidomain functional</description>
</item>
<item>
<title>Neurogene to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-participate-upcoming-investor-conferences-123000444</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-participate-upcoming-investor-conferences-123000444</guid>
<pubDate>Thu, 05 Feb 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, February 05, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:</description>
</item>
<item>
<title>Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-inducement-grant-under-210100947</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-inducement-grant-under-210100947</guid>
<pubDate>Wed, 04 Feb 2026 21:01:00 GMT</pubDate>
<description>NEW YORK, February 04, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company’s common stock to one new employee (the "Inducement Grant") on February 2, 2026 (the "Grant Date"). The Inducem</description>
</item>
<item>
<title>Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-recent-achievements-anticipated-120000320</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-recent-achievements-anticipated-120000320</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, January 12, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on recent achievements for NGN-401 gene therapy for the treatment of Rett syndrome and plans for multiple value-creating catalysts anticipated in 2026.</description>
</item>
<item>
<title>Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-participate-44th-annual-j-123000849</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-participate-44th-annual-j-123000849</guid>
<pubDate>Mon, 05 Jan 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, January 05, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the 44th Annual J.P. Morgan Healthcare Conference.</description>
</item>
<item>
<title>Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-inducement-grants-under-210100058</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-inducement-grants-under-210100058</guid>
<pubDate>Thu, 04 Dec 2025 21:01:00 GMT</pubDate>
<description>NEW YORK, December 04, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,860 shares of the Company’s common stock to two new employees (the "Inducement Grants") on December 2, 2025 (the "Grant Date"). The Induc</description>
</item>
<item>
<title>Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-reports-third-quarter-2025-221000558</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-reports-third-quarter-2025-221000558</guid>
<pubDate>Thu, 13 Nov 2025 22:10:00 GMT</pubDate>
<description>NEW YORK, November 13, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2025 financial results and highlighted recent corporate updates.</description>
</item>
<item>
<title>Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-reports-positive-interim-data-210100489</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-reports-positive-interim-data-210100489</guid>
<pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
<description>NEW YORK, November 12, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive, updated interim clinical data in the pediatric cohort (ages 4-10 cohort) from its ongoing Phase 1/2 trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome.</description>
</item>
<item>
<title>Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-first-participant-dosed-123000884</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-first-participant-dosed-123000884</guid>
<pubDate>Thu, 06 Nov 2025 12:30:00 GMT</pubDate>
<description>NEW YORK, November 06, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden™ registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome. NGN-401 has the potential to be a best-in-class and first-in-class gene therapy for Rett syndrome, a neurodevelopmental dis</description>
</item>
<item>
<title>Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-positive-regulatory-ngn-110000519</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-positive-regulatory-ngn-110000519</guid>
<pubDate>Thu, 09 Oct 2025 11:00:00 GMT</pubDate>
<description>NEW YORK, October 09, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the Company has completed discussions with the U.S. Food and Drug Administration (FDA) on its Embolden™ registrational trial protocol and plans to initiate dosing in the fourth quarter of 2025. In response to strong interest from the Rett syndrome community, the trial is expected to en</description>
</item>
<item>
<title>Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-participate-h-c-wainwright-113000096</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-participate-h-c-wainwright-113000096</guid>
<pubDate>Wed, 08 Oct 2025 11:30:00 GMT</pubDate>
<description>NEW YORK, October 08, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference.</description>
</item>
<item>
<title>Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-reports-second-quarter-2025-201000072</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-reports-second-quarter-2025-201000072</guid>
<pubDate>Mon, 11 Aug 2025 20:10:00 GMT</pubDate>
<description>NEW YORK, August 11, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates.</description>
</item>
<item>
<title>Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-registrational-trial-design-200100369</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-registrational-trial-design-200100369</guid>
<pubDate>Mon, 30 Jun 2025 20:01:00 GMT</pubDate>
<description>NEW YORK, June 30, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced details of Embolden™, the Company’s registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years and older. The Company has written agreement from the U.S. Food and Drug Administration (FDA) on key asp</description>
</item>
<item>
<title>Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-evidence-based-monitoring-110000821</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-evidence-based-monitoring-110000821</guid>
<pubDate>Fri, 16 May 2025 11:00:00 GMT</pubDate>
<description>NEW YORK, May 16, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting describing a monitoring and treatment algorithm intended to reverse the rare, severe hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH) that has been associated with systemic expos</description>
</item>
<item>
<title>Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-reports-first-quarter-2025-113000429</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-reports-first-quarter-2025-113000429</guid>
<pubDate>Fri, 09 May 2025 11:30:00 GMT</pubDate>
<description>NEW YORK, May 09, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates.</description>
</item>
<item>
<title>Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting</title>
<link>https://6ix.com/company/neurogene-inc/news/neurogene-announces-upcoming-oral-presentation-210000118</link>
<guid isPermaLink="true">https://6ix.com/company/neurogene-inc/news/neurogene-announces-upcoming-oral-presentation-210000118</guid>
<pubDate>Mon, 28 Apr 2025 21:00:00 GMT</pubDate>
<description>NEW YORK, April 28, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation and participation in a fireside chat and panel discussion on critical gene therapy topics during the American Society for Gene and Cell Therapy (ASGCT) 28th Annual Meeting on May 13-17, 2025 in New Orleans. The oral presentation will include approaches for monitoring</description>
</item>
</channel>
</rss>